Search results
Added:
9 months ago
Source:
Radcliffe CVRM
The assessment of lipid-related cardiovascular risk has traditionally focused on low-density lipoprotein cholesterol (LDL-C), but debate continues over the relative atherogenicity of different apolipoprotein B-containing lipoprotein particles (apoB-P). A large prospective analysis published in the European Heart Journal provides clarity, suggesting that the total count of apoB-P and lipoprotein(a…
View more
Added:
2 months ago
Source:
Radcliffe CVRM
The human metabolome reflects a complex interplay of genetic and environmental factors. A large-scale analysis integrating blood metabolomic, genomic, and lifestyle data from ten prospective cohorts has identified a comprehensive profile of circulating metabolites that are associated with the future risk of developing type 2 diabetes (T2D).¹MethodologyResearchers conducted a pooled analysis of 23…
View more
Added:
1 month ago
Source:
Radcliffe CVRM
For patients with elevated lipoprotein(a) [Lp(a)] and established cardiovascular disease (CVD), weekly lipoprotein apheresis (LA) is the only approved treatment, but it represents a significant burden. The Lp(a)FRONTIERS APHERESIS trial investigated whether the investigational therapy pelacarsen could reduce the need for this invasive procedure.¹Mechanism of ActionPelacarsen is a hepatocyte…
View more
Added:
11 months ago
Source:
Radcliffe CVRM
AUTHOR: Ola WisniewskaSodium-glucose cotransporter-2 (SGLT2) inhibitors significantly slow kidney function decline in patients with type 2 diabetes, with even greater benefits seen in those with higher body mass index (BMI), according to a nationwide Japanese study published recently.1Researchers analyzed data from 2,165 patients prescribed SGLT2 inhibitors compared with 4,330 matched patients on…
View more
Added:
3 months ago
Source:
Radcliffe CVRM
A new study has defined a metabolome-informed body mass index (metBMI) that more accurately reflects adiposity and cardiometabolic risk than the traditional BMI calculation.² The findings, published in Nature Medicine, suggest this multi-omic approach could help identify high-risk individuals whose metabolic dysfunction is not captured by conventional measures.¹MethodologyResearchers developed…
View more
Added:
4 months ago
Source:
Radcliffe CVRM
Elevated lipoprotein(a) [Lp(a)] is a known causal risk factor for atherosclerotic cardiovascular disease (ASCVD), with vascular inflammation considered a key mechanism.² A new analysis has investigated whether interleukin-6 (IL-6), a biomarker of inflammation, can help to further stratify cardiovascular risk in individuals with elevated Lp(a). The study analysed data from two large, independent…
View more
Added:
7 months ago
Source:
Transcatheter Academy
The use of paclitaxel-coated devices did not reduce the rate of major amputations or death in patients with chronic limb-threatening ischaemia (CLTI) undergoing infrainguinal endovascular revascularisation, according to the results of a large registry-based trial.¹ While drug-coated devices are commonly used in peripheral interventions, their effect on amputation risk has been uncertain.²The…
View more
Added:
8 months ago
Source:
Radcliffe CVRM
Traditional methods for diagnosing and monitoring type 2 diabetes (T2D), such as episodic glycated haemoglobin (HbA1c) assays, may not fully capture the complex, multifaceted nature of the disease. A new study suggests that a multimodal artificial intelligence (AI) approach, integrating data from wearables, genomics, and the gut microbiome, can provide a more detailed and informative phenotype…
View more
Added:
5 months ago
Source:
Radcliffe CVRM
Patients receiving maintenance haemodialysis have a cardiovascular mortality rate more than 20 times higher than the general population, and many standard preventative therapies have proven ineffective in this high-risk group. The results of a new randomised clinical trial, PISCES, suggest that daily supplementation with fish oil could offer a significant benefit, substantially reducing the rate…
View more
Added:
1 year ago
Source:
European Renal Association
The SELECT Trial has revealed the potential of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in combating kidney function decline among individuals with overweight or obesity and established cardiovascular disease but without diabetes.1Unveiling the results today at the 61st ERA Congress, researchers presented the impressive secondary analysis from the SELECT (Semaglutide…
View more